# Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases

> **NCT07481786** · PHASE3 · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 220 (estimated)

## Conditions studied

- Lung Adenocarcinoma
- Brain Metastases
- Radiotherapy, Intensity-Modulated
- Bevacizumab
- Whole-Brain Radiotherapy

## Interventions

- **RADIATION:** FSRT
- **RADIATION:** HA-WBRT-SIB
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT07481786
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-20
- **Primary completion:** 2029-09-15
- **Final completion:** 2029-09-15
- **Target enrollment:** 220 (ESTIMATED)
- **Last updated:** 2026-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07481786

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07481786, "Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT07481786. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*